Although a major limitation of our study is that we could not use mapatumumab in our setting, it is possible that combination therapy with mapatumumab and molecular targeted agents against RCC requires the suppression of IL-6 signaling for better effects, as IL-6 signaling induces SOCS3 expression. Here, SOCS3 is linked to renal cell carcinoma.